News and Insights of 3D Printing and Manufacturing
French medical device company PROTEOR has acquired Filament Innovations, a company specializing in 3D printing technologies for the orthotics and prosthetics (O&P) industry. The acquisition broadens PROTEOR’s digital solutions portfolio to include scanning, rectification, and 3D printing tools, supporting the development of customized medical device solutions.
Austrian ceramic 3D printing company Lithoz has achieved a 92% success rate in a clinical long-term follow-up study of its beta TCP patient-specific implants (PSI). The study confirmed that its 3D printed implants made using Lithoz’s CeraFab printer are effective bone substitutes, showing strong osteoconductive and osteoinductive properties with no post-surgical complications. The study’s findings aim to support the broader clinical adoption of ceramic 3D printing in surgical applications.
US-based 3D printer manufacturer 3D Systems has announced the successful use of its point-of-care additive manufacturing solution to produce the world’s first MDR-compliant 3D printed facial implant. Designed and printed within University Hospital Basel, Switzerland, the patient-specific PEEK implant was used in a maxillofacial reconstruction surgery on March 18, 2025.
The EU-funded Keratoprinter project is developing a new 3D bioprinting platform to create full-thickness, curved human corneas. Aimed at tackling the global shortage of donor tissue, the initiative seeks to restore vision for millions affected by corneal blindness while prioritizing sustainability and patient-specific care.
Stratasys Ltd. (NASDAQ: SSYS), a global provider of polymer 3D printers, has announced new strategic partnerships with three European dental distributors: Nueva Galimplant (Spain), Gold Quadrat (Germany), and Metaux Precieux (Germany). These collaborations will expand the reach of Stratasys’ dental 3D printing portfolio, including TrueDent™, a full-color, monolithic digital denture solution. Stratasys’ dental offering includes mixed-application printing, such as crowns, bridges, and orthodontic models, on a single tray, streamlining workflows and enabling mass customization. These features are especially attractive to labs seeking to increase throughput without scaling labor. During IDS 2025, the leading European dental trade fair, Stratasys exhibited its multi-material 3D printing capabilities across dental applications, from orthodontics to crowns and bridges.
Triastek, a Chinese 3D printing pharmaceutical company, has announced that its proprietary 3D printed non-vitamin K antagonist oral anticoagulant (NOAC), T20G, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) as of February 27, 2025. This regulatory achievement follows an earlier IND approval from China’s National Medical Products Administration (NMPA) in January 2024.
Axtra3D, a developer of high-speed stereolithography (SLA) systems, has introduced four new dental resins, expanding its portfolio of validated materials for the Lumia X1 printer. The new additions—NextDent Model Sand, Pro3dure Splint 19.1 AO/MSI, Pro3dure Denture 14.2, and Pro3dure Crown & Bridge—are now available with optimized print profiles, aimed at increasing accuracy and production efficiency for digitally manufactured dental models, splints, dentures, and restorations.
A group of Chinese researchers have developed a novel approach for addressing erectile dysfunction (ED) using biomedical 3D printing.
At IDS 2025, Carbon, a U.S.-based developer of CLIP 3D printing, will showcase its latest advancements in automation, material technology, and workflow optimization, all designed to enhance the efficiency of dental labs. The company will introduce new features in its Automatic Operation (AO) Suite and unveil Lucentra, a solution for clear aligner production. These innovations aim to improve productivity and support scalable production in the dental industry.
Researchers at RWTH Aachen University’s Chair Digital Additive Production (DAP), working with the reACT alliance, are developing bioresorbable implants designed to fit each patient’s needs.